XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value - Additional Information (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 31, 2023
USD ($)
Installment
Apr. 07, 2022
Oct. 31, 2024
USD ($)
Jul. 31, 2024
USD ($)
Apr. 30, 2024
USD ($)
Installment
Apr. 30, 2022
USD ($)
Installment
Mar. 31, 2024
USD ($)
shares
Mar. 31, 2023
USD ($)
Dec. 31, 2018
USD ($)
Installment
shares
Nov. 21, 2022
shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Change in fair value of warrant liability               $ (61)    
2018 Notes | Series G Preferred Stock                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Warrant issued to purchase shares | shares             613,333      
Contingent Consideration                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Interest expense due to passage of time and fixed payment schedule             $ 700 1,100    
Warrant Liabilities                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Warrant issued to purchase shares | shares                   5,000,000
Change in fair value of warrant liability             $ 0 $ 100    
Integrated Diagnostics, Inc | Contingent Consideration                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Business acquisition description             requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month      
Business acquisition contingent consideration gross margin target                 $ 2,000  
Business acquisition contingent consideration gross margin target period                 7 years  
Integrated Diagnostics, Inc | Contingent Consideration | Third Amendment to APA Agreement                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Contingent consideration number of installments | Installment 3         5        
Milestone payment $ 3,000         $ 2,000        
Percentage of interest on installment payments   10.00%                
Integrated Diagnostics, Inc | Contingent Consideration | Subsequent Event | Third Amendment to APA Agreement                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Contingent consideration number of installments | Installment         1          
Milestone payment         $ 5,000          
Integrated Diagnostics, Inc | Contingent Consideration | Scenario Forecast | Third Amendment to APA Agreement                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Milestone payment       $ 8,400            
Exit fee payment     $ 6,100              
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Business acquisition description             If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.      
Contingent consideration shares | shares                 2,520,108  
Contingent consideration number of installments | Installment                 8  
Contingent consideration arrangements, common shares, redemption amount             $ 4,600   $ 37,000  
Repayments of debt             9,300      
Business combination contingent consideration final payment             $ 37,000      
Contingent consideration cash payment                 $ 37,000  
Investment, Type [Extensible Enumeration]                 Repurchase [Member]  
Minimum | Contingent Consideration                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range             11.00%      
Maximum | Contingent Consideration                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range             16.00%